Stephen Johnston, ESMO 2020 – The MonarchE trial and Abemaciclib in High-risk Early Breast Cancer
Prof. Stephen Johnston discusses the recent phase III MonarchE trial, the data presented at the Virtual 2020 ESMO Congress, and the role of abemaciclib in the treatment of HR+, HER2-, high-risk early breast cancer. Prof Johnston presented the late-breaking abstract ‘Abemaciclib in high risk early breast cancer’ (LBA5_PR) during the Virtual 2020 ESMO Congress, 19–21 September 2020.
- What are the unmet needs in the treatment of HR-positive, HER2-negative early breast cancer and what factors influence the likelihood of recurrence? (0:12)
- Could you tell us a little about the aims, design and findings of the MonarchE clinical trial? (1:15)
- What is the clinical significance of these findings and how are they likely to impact on future clinical practice? (2:45)
- What other agents that could be effectively combined with CDK4/6 inhibitors, beyond endocrine therapy? (4:09)
- What will be the next steps in the clinical development of abemaciclib in breast cancer therapy? (6:02)
Speaker Disclosures: Stephen Johnston has provided consultancy for Novartis, Pfizer, Eli Lilly, Puma Biotechnology; has received speaker honoraria from Eisai, AstraZeneca, Eli Lilly, Novartis, Pfizer, Roche; and has received research funding for his institution from Pfizer, Puma Biotechnology, Eli Lilly, AstraZeneca, Novartis, Roche/Genentech.
Support: Interview and filming supported by Touch Medical Media Ltd. The MonarchE trial was sponsored by Eli Lilly and Company.
Filmed in coverage of the Virtual 2020 ESMO Congress.
Share this Video
Related Videos In Breast Cancer
Sara Hurvitz, SABCS 2022: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2+ metastatic breast cancer: DESTINY-Breast03
Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients with HER2+ unresectable/metastatic breast cancer. Approval was based on the randomized, multicenter, open-label, phase III DESTINY-Breast03 (NCT03529110) trial. In this interview we discuss with Dr Sara Hurvitz (David Geffen School of Medicine, UCLA Los Angeles, CA, USA) updated data […]
Erika Hamilton, SABCS 2022: Trastuzumab deruxtecan and pertuzumab in HER2+ metastatic breast cancer
Preclinical findings have suggested that when used in combination with anticancer treatments, trastuzumab deruxtecan (T-Dxd) could improve treatment efficacy in HER2+ metastatic breast cancer (mBC). In this interview we discuss with Dr Erika Hamilton (Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN) preliminary data from the dose expansion phase of the DESTINY-Breast07 (DB-07) (NCT04538742) trial. […]
Sudeep Gupta, SABCS 2022: Addition of platinum to neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial
The impact of adding platinum on long-term outcomes in triple-negative breast cancer (TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!